JP2023542900A5 - - Google Patents
Info
- Publication number
- JP2023542900A5 JP2023542900A5 JP2023517935A JP2023517935A JP2023542900A5 JP 2023542900 A5 JP2023542900 A5 JP 2023542900A5 JP 2023517935 A JP2023517935 A JP 2023517935A JP 2023517935 A JP2023517935 A JP 2023517935A JP 2023542900 A5 JP2023542900 A5 JP 2023542900A5
- Authority
- JP
- Japan
- Prior art keywords
- domain antibody
- cancer
- fusion protein
- antibody according
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010981835 | 2020-09-17 | ||
| CN202010981835.5 | 2020-09-17 | ||
| CN202011025265.9A CN114195894B (zh) | 2020-09-17 | 2020-09-25 | 一种靶向4-1bb的抗体及其应用 |
| CN202011025265.9 | 2020-09-25 | ||
| PCT/CN2021/118955 WO2022057875A1 (zh) | 2020-09-17 | 2021-09-17 | 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542900A JP2023542900A (ja) | 2023-10-12 |
| JP2023542900A5 true JP2023542900A5 (https=) | 2024-09-18 |
Family
ID=80645420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517935A Pending JP2023542900A (ja) | 2020-09-17 | 2021-09-17 | ４－１ｂｂを標的とする単一ドメイン抗体、その融合タンパク質、その医薬組成物及び使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230357422A1 (https=) |
| EP (1) | EP4215547A4 (https=) |
| JP (1) | JP2023542900A (https=) |
| KR (1) | KR20230070238A (https=) |
| CN (2) | CN114195894B (https=) |
| AU (1) | AU2021342525A1 (https=) |
| CA (1) | CA3195676A1 (https=) |
| WO (1) | WO2022057875A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119894933A (zh) * | 2022-09-20 | 2025-04-25 | 普米斯生物技术(珠海)有限公司 | 抗体及其在抗肿瘤中的应用 |
| TW202436358A (zh) * | 2023-03-01 | 2024-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及其醫藥用途 |
| WO2025002405A1 (zh) * | 2023-06-30 | 2025-01-02 | 百奥泰生物制药股份有限公司 | 4-1bb结合蛋白 |
| CN117736330B (zh) * | 2024-01-24 | 2024-05-17 | 上海沙砾生物科技有限公司 | 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用 |
| WO2025214249A1 (en) * | 2024-04-12 | 2025-10-16 | Suzhou Biomissile Pharmaceuticals Co., Ltd. | Anti-4-bb single domain antibodies, bispecific antibodies and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| MX337040B (es) * | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| CN112210010B (zh) * | 2017-01-06 | 2023-12-05 | 优特力克斯有限公司 | 抗-人4-1bb抗体及其应用 |
| EP3710478A1 (en) * | 2017-11-13 | 2020-09-23 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| WO2019109238A1 (en) * | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| CN109970865B (zh) * | 2017-12-28 | 2022-10-04 | 上海细胞治疗研究院 | 一种cd137双向激活共刺激分子受体及其用途 |
| KR20200113228A (ko) * | 2018-01-22 | 2020-10-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-4-1bb 항체, 이의 항원-결합 단편 및 이의 의학적 용도 |
| EP3827019A1 (en) * | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CN112646031B (zh) * | 2019-10-10 | 2021-12-07 | 天境生物科技(上海)有限公司 | 抗4-1bb纳米抗体及其用途 |
-
2020
- 2020-09-25 CN CN202011025265.9A patent/CN114195894B/zh active Active
-
2021
- 2021-09-17 AU AU2021342525A patent/AU2021342525A1/en active Pending
- 2021-09-17 US US18/245,691 patent/US20230357422A1/en active Pending
- 2021-09-17 CN CN202180062285.XA patent/CN116490206A/zh active Pending
- 2021-09-17 KR KR1020237012083A patent/KR20230070238A/ko active Pending
- 2021-09-17 EP EP21868697.0A patent/EP4215547A4/en active Pending
- 2021-09-17 WO PCT/CN2021/118955 patent/WO2022057875A1/zh not_active Ceased
- 2021-09-17 JP JP2023517935A patent/JP2023542900A/ja active Pending
- 2021-09-17 CA CA3195676A patent/CA3195676A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023542900A5 (https=) | ||
| CN109096401B (zh) | 抗Her2纳米抗体及其编码序列和用途 | |
| JP2025163055A5 (https=) | ||
| JP2022515318A5 (https=) | ||
| JP2023539501A5 (https=) | ||
| JP2018502050A5 (https=) | ||
| AU2015308894A1 (en) | Internalizing moieties for treatment of cancer | |
| JP2022527151A5 (https=) | ||
| JP2024544520A5 (https=) | ||
| CN111378044B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| US20230279115A1 (en) | Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof | |
| CN110770252A (zh) | 抗p53抗体 | |
| WO2018166507A1 (zh) | 新型重组双功能融合蛋白及其制备方法和用途 | |
| CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| JP2022512672A5 (https=) | ||
| JP2024542944A5 (https=) | ||
| WO2021113748A1 (en) | Composition of triaxial antibodies and method of making and using thereof | |
| WO2024001669A1 (zh) | 靶向itga2的抗体和包含此抗体的抗体药物缀合物 | |
| JP2025513930A5 (https=) | ||
| CN118754989B (zh) | 一种抗her2纳米抗体及其制备方法和应用 | |
| CN117659194B (zh) | 靶向egfr的纳米抗体、药物偶联物及其用途 | |
| JP7378088B2 (ja) | ｈＥＲＧ１およびｈＥＲＧ１／インテグリンβ１に結合する単一特異性および二重特異性抗体 | |
| WO2004003211A1 (en) | Bispecific antibodies that bind to vegf receptors | |
| WO2023222135A9 (en) | A method of treating solid tumor | |
| CN115124621B (zh) | 靶向pd-l1的纳米抗体及其制备方法和应用 |